Table 2.
GMTs to each DENV serotype 28 days (ATP cohort for immunogenicity D56), 6 months (ATP cohort for immunogenicity M7), and 12 months (ATP cohort for immunogenicity M13) after the second vaccine dose
| Serotype and group | Post-dose 2 (D56) | Post-dose 2 (M7) | Post-dose 2 (M13) | ||||
|---|---|---|---|---|---|---|---|
| N | GMT (95% CI) | N | GMT (95% CI) | N | GMT (95% CI) | ||
| DENV-1 | 1 μg + alum | 17 | 55 (34–88) | 18 | 7 (5–10) | 17 | 8 (5–12) |
| 4 μg + alum | 16 | 179 (118–271) | 17 | 14 (9–21) | 17 | 13 (9–20) | |
| 1 μg + AS01E | 13 | 411 (215–785) | 12 | 21 (10–47) | 12 | 31 (10–101) | |
| 1 μg + AS03B | 16 | 526 (311–889) | 16 | 33 (19–58) | 14 | 25 (12–53) | |
| Placebo | 16 | 5 (5–5) | 17 | 5 (5–5) | 17 | 5 (5–5) | |
| DENV-2 | 1 μg + alum | 17 | 34 (19–59) | 18 | 6 (5–7) | 17 | 7 (5–11) |
| 4 μg + alum | 16 | 155 (91–265) | 17 | 14 (8–23) | 17 | 9 (6–15) | |
| 1 μg + AS01E | 13 | 484 (231–1,016) | 12 | 20 (9–46) | 12 | 27 (11–68) | |
| 1 μg + AS03B | 16 | 341 (175–663) | 16 | 23 (12–41) | 14 | 17 (9–34) | |
| Placebo | 16 | 5 (5–5) | 17 | 5 (5–5) | 17 | 5 (5–5) | |
| DENV-3 | 1 μg + alum | 17 | 54 (35–82) | 18 | 6 (5–7) | 17 | 6 (5–7) |
| 4 μg + alum | 16 | 191 (117–312) | 17 | 13 (9–19) | 17 | 9 (6–15) | |
| 1 μg + AS01E | 13 | 539 (275–1,059) | 12 | 21 (10–46) | 12 | 37 (15–91) | |
| 1 μg + AS03B | 16 | 468 (296–741) | 16 | 29 (14–63) | 14 | 24 (12–50) | |
| Placebo | 16 | 5 (5–5) | 17 | 5 (5–5) | 17 | 5 (5–5) | |
| DENV-4 | 1 μg + alum | 17 | 20 (8–47) | 18 | 6 (5–7) | 17 | 5 (5–6) |
| 4 μg + alum | 16 | 141 (58–345) | 17 | 9 (5–16) | 17 | 7 (4–13) | |
| 1 μg + AS01E | 13 | 307 (96–976) | 12 | 7 (4–15) | 12 | 9 (4–22) | |
| 1 μg + AS03B | 16 | 406 (192–859) | 16 | 15 (7–35) | 14 | 8 (5–14) | |
| Placebo | 16 | 5 (5–5) | 17 | 5 (5–5) | 17 | 5 (5–5) | |
1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B; ATP = according-to-protocol; GMTs = geometric mean antibody titers calculated on all participants (participants with a titer below the assay cutoff of 10 were attributed the arbitrary value of 5); Post-dose 2 (D56) = blood sampling 28 days post-dose 2 at Day 56; Post-dose 2 (M7) = blood sampling 6 months post-dose 2; Post-dose 2 (M13) = blood sampling 12 months post-dose 2; N = number of subjects with available data; 95% CI = 95% confidence interval.